Scarica l'app Stockscreener
2.25
0.88%
-0.02
Dopo l'orario di chiusura:
2.27
0.02
+0.89%
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to S&P Biotechnology Select Industry Index - marketscreener.com
Ovid Therapeutics Inc (OVID) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ovid Therapeutics (NASDAQ: OVID) grants director Anna Greka 130,000 stock options - Stock Titan
Ovid Therapeutics (OVID) director files initial Form 3 - Stock Titan
Ovid Therapeutics Inc (OVID) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ovid Therapeutics Inc (OVID) Institutional Confidence - TradingKey
Ovid Therapeutics Inc (OVID) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ovid Therapeutics Inc (OVID) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ovid Therapeutics Inc (OVID) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ovid Therapeutics Inc (OVID) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ovid Therapeutics Inc (OVID) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ovid Therapeutics Inc (OVID) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OVID: Multiple clinical milestones and strong financial runway position the pipeline for significant value creation - TradingView
Ovid Therapeutics Shareholders Back Board and Governance Proposals - The Globe and Mail
Ovid Therapeutics (OVID) Slips 1.97% as Shares Test Key Support LevelsStrong Buy Stocks - newsline.com
Ovid Therapeutics (NASDAQ: OVID) shareholders approve director, pay and auditor - Stock Titan
Ovid Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Ovid Board Move Puts Scientific Strategy Back In Focus - Kalkine Media
Ovid Therapeutics Expands Board, Appoints New Scientific Director - The Globe and Mail
Ovid Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Ovid Therapeutics appoints Anna Greka to board of directors - Investing.com UK
Ovid Therapeutics appoints Anna Greka to board of directors By Investing.com - Investing.com Canada
Anna Greka joins Ovid Therapeutics (NASDAQ: OVID) board, expanding it to seven - Stock Titan
Ovid Therapeutics Appoints Leading Physician-Scientist and - GlobeNewswire
OVIDOvid Therapeutics Inc Stock Price and Quote - Finviz
Ovid Therapeutics (OVID) Gains Nearly 4% as Shares Test Key ResistanceUnusual Put Volume - newsline.com
Will Ovid’s golden age of KCC2 metamorph CNS? - BioWorld News
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4 - Moomoo
OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Point72 (OVID) discloses shared 1.3% position, including warrants - Stock Titan
Eventide (OVID) discloses 12.8M-share, 7.3% position in Ovid Therapeutics - Stock Titan
Ovid Therapeutics (OVID) Schedule 13G: Sirenia/manager report 9.9% stake - Stock Titan
Balyasny group holds 5.33% of Ovid (NASDAQ: OVID) across funds - Stock Titan
[SCHEDULE 13G/A] Ovid Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Jeremy Levin reports 4.5% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely - Yahoo Finance
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $7 - Moomoo
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com India
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo
Ovid Therapeutics 1Q Research and Development Expenses $11.2M >OVID - Moomoo
William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo
Ovid Therapeutics earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
OVID Sets Stage for Future Growth with Promising Pipeline Develo - GuruFocus
Ovid Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Ovid Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ovid Therapeutics Reports Q1 2026 Results, Advances OV329 and OV4071 Clinical Programs, and Expands Pipeline for Pediatric Epilepsy and Psychosis 123 - Minichart
Ovid Therapeutics stock rises 4% on in-line results, pipeline progress By Investing.com - Investing.com South Africa
Ovid Therapeutics stock rises 4% on in-line results, pipeline progress - Investing.com UK
0.57%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):